News updates

Revised Cost Estimate (RCE) Approval

posted May 21, 2014, 2:46 AM by Anshu Bhardwaj   [ updated May 21, 2014, 3:14 AM ]

Revised Cost Estimate (RCE) for OSDD project for the year 2014-2015 has been approved (RCE OM attached).

Charge handover

posted May 21, 2014, 2:44 AM by Anshu Bhardwaj   [ updated May 21, 2014, 3:12 AM ]

Shri Zakir Thomas, Project Director has repatriated to his parent department on 31st March, 2014 and the charge has been handed over to Dr Sarala Balachandran (Charge handover OM attached).

OSDD Launches the Phase II B clinical trials of PaMZ

posted Mar 26, 2014, 10:24 PM by Anshu Bhardwaj   [ updated May 1, 2014, 2:22 AM ]


24 March 2014: Open Source Drug Discovery launched the Phase II B clinical trials of  the new combination drug for TB -PaMZ in collaboration with the National Institute of Tuberculosis & Respiratory Diseases, New Delhi. The proposed trial is a three arm trial examining the safety and efficacy of the said combination on multi-drug resistant tuberculosis in Indian patients. The protocols for the Phase IIB clinical trials of PaMZ was released by Dr. T Ramasami, Secretary , DST and Director General CSIR in presence of  Dr. V. M Katoch Secretary, Department of Health Research & Director General, ICMR, Dr. Jagdish Prasad, Director General of Health Services and Dr. Rohit Sarin , Director, NITRD. NITRD is the Investigator institute and Dr Rohit Sarin is the Principal Investigator.  

 

 

 






CSIR- OSDD’s First Clinical Trials Approved

posted Jan 27, 2014, 11:41 PM by Anshu Bhardwaj

The Drug Controller General of India has accorded approval for CSIR-OSDD’s proposal (OSDD-TBCT-001) to conduct a Phase IIb clinical trial of a novel combination therapy for MDR TB patients. The trial involves  3 arms, a new combination of PA 824 in a combination of PA 824, Moxifloxacin and Pyrazinamide, a second arm of  Pa824 as an add on drug to the current Standard of Care ( DOTS PLUS) and the 3rd arm consisting of the Standard of Care. The new molecule and the novel combination are brought into Clinical Trials in India in collaboration with Global Alliance on Tuberculosis (TB Alliance). The trial is a partnership with National Institute of Tuberculosis and Respiratory Diseases (formerly LRS Hospital), Delhi, an institution under the Ministry of Health which is the Investigator hospital.  National Institute for Research in Tuberculosis (formerly TRC), Chennai, an ICMR institute supported the design of the Trails. M/s G V K Biosciences is the Clinical Research Organization supporting the Trials. If the trials (including Phase III) are successful, the drugs will be available at an affordable cost as it will be available for manufacture in India without any royalty to OSDD.

Crowdsourcing Drug Discovery

posted Dec 26, 2013, 8:10 AM by Anshu Bhardwaj   [ updated Jan 20, 2014, 10:22 PM ]

The RSC and CSIR-OSDD Ambassador Awards for OSDD Community Members - extended last date for participation



Design Chemists for Drug Discovery



The Royal Society Chemistry (RSC)-


CSIR-Open Source Drug Discovery (OSDD) 


Jointly organizing 


3 Day Hands-on Interactive workshop


3-5 February 2014, CSIR-NCL, Pune, India


Register here to participate


(The registrations will be open from 30th Dec 2013 and will be open till 27th Jan 2014)


The detailed agenda of the workshop may be seen here


Apply for TATA CSIR-OSDD Fellowship

posted Nov 7, 2013, 12:46 AM by Anshu Bhardwaj   [ updated Nov 7, 2013, 12:51 AM ]

The TATA CSIR-OSDD fellowship now offers a unique opportunity to students across the universities to undertake research and contribute towards the OSDD vision of providing affordable healthcare for all.

For more details and to apply for the fellowship please click here 

Prof. Samir Brahmachari’s Invited Lecture on Open Source Drug Discovery at Norway

posted Oct 28, 2013, 10:45 PM by Anshu Bhardwaj   [ updated Oct 28, 2013, 10:59 PM ]

On the invitation of the Norway Biotechnology Board, an independent scientific body appointed by the Norwegian government, Prof. Samir Brahmachari, Director General, CSIR and Chief Mentor, OSDD, delivered lecture on ‘Open Source Drug Discovery as an Innovative Model for Affordable Healthcare for All’ at three top universities of Norway. Prof. Brahmachari presented the concept of OSDD to large audience at University of Oslo, University of Trondheim and University of Tromso during 21-24th November 2013. In an interview with The Norwegian Broadcasting Corporation, Prof. Brahmachari expressed his concern on the lack of new drugs for neglected diseases like Tuberculosis and raising the hope of innovative medical discoveries by involving young researchers in drug discovery.

Link to Prof. Brahmachari’s interview:

 http://tv.nrk.no/serie/urix/nnfa53102213/22-10-2013#t=14m37s


   Bringing Together Global Volunteers for Affordable Drugs

TATA CSIR-OSDD Fellowship

posted Oct 21, 2013, 5:22 AM by Anshu Bhardwaj   [ updated Oct 21, 2013, 5:54 AM ]

Sir Dorabji Tata Trust has awarded a Grant to enable Council of Scientific & Industrial Research (CSIR), New Delhi for operating TATA CSIR-OSDD Fellowship (TCOF) to support students and young researchers who will participate in the process of “crowd sourcing” as a method of research on open source discovery of drugs for neglected diseases like Tuberculosis (TB) and Malaria. The Grant amounts to Rs.285.75 lakhs for a period of 3 years.

OSDD Linux

posted Sep 30, 2013, 3:51 AM by Anshu Bhardwaj   [ updated Oct 14, 2013, 5:57 AM ]

An open source Operating System for drug discovery (customized Linux), developed by Dr. G.P.S Raghava's group  (CSIR- IMTech )  is available for download. This integrates most of the open source/freely available computational tools for drug discovery and provides an, in silico platform for computer aided drug design. Click here to know more about OSDD Linux






1-9 of 9